PRELUDE THERAPEUTICS INC's ticker is PRLD and the CUSIP is 74065P101. A total of 63 filers reported holding PRELUDE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $12,961,196 | 0.0% | 2,273,894 | 0.0% | 0.01% | 0.0% |
| Q1 2023 | $12,961,196 | -8.1% | 2,273,894 | -2.7% | 0.01% | -14.3% |
| Q4 2022 | $14,109,102 | -99.9% | 2,335,944 | -2.8% | 0.01% | -22.2% |
| Q3 2022 | $15,881,153,000 | +25.7% | 2,402,595 | -0.7% | 0.01% | +28.6% |
| Q2 2022 | $12,635,151,000 | -24.4% | 2,420,527 | -0.1% | 0.01% | 0.0% |
| Q1 2022 | $16,714,056,000 | -11.3% | 2,422,327 | +60.0% | 0.01% | 0.0% |
| Q4 2021 | $18,845,391,000 | -59.3% | 1,513,686 | +2.0% | 0.01% | -63.2% |
| Q3 2021 | $46,353,719,000 | +25.7% | 1,483,319 | +15.2% | 0.02% | +18.8% |
| Q2 2021 | $36,867,853,000 | +32.3% | 1,287,735 | +100.3% | 0.02% | +33.3% |
| Q1 2021 | $27,860,280,000 | -24.5% | 642,979 | +24.6% | 0.01% | -29.4% |
| Q4 2020 | $36,921,875,000 | +68.7% | 516,029 | -29.0% | 0.02% | +41.7% |
| Q3 2020 | $21,888,330,000 | – | 726,463 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Orbimed Advisors | 10,909,256 | $41,564,265 | 0.82% |
| Boxer Capital, LLC | 2,568,287 | $9,785,173 | 0.52% |
| Baker Brothers Advisors | 10,123,824 | $38,571,769 | 0.49% |
| Sio Capital Management, LLC | 320,394 | $1,220,701 | 0.33% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 4,133,000 | $15,746,730 | 0.26% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 123,600 | $470,916 | 0.01% |
| EXCHANGE TRADED CONCEPTS, LLC | 48,727 | $185,650 | 0.01% |
| Y-Intercept (Hong Kong) Ltd | 18,839 | $71,777 | 0.00% |
| PRELUDE CAPITAL MANAGEMENT, LLC | 11,074 | $42,192 | 0.00% |
| KENNEDY CAPITAL MANAGEMENT LLC | 35,283 | $134,428 | 0.00% |